Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Hereditary Hemochromatosis
Interventions: LJPC-401, Placebo; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Intracerebral Hemorrhage
Interventions: Deferoxamine Mesylate, Placebo (for Deferoxamine Mesylate); Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 25
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 18 more

Conditions: Anhedonia, Depression
Interventions: Endotoxin, Placebo; Biological
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 25 Years to 44 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 1
Interventions: Antithymocyte Globulin, Placebo (for ATG); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 34 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Orange, California • San Francisco, California • Stanford, California + 17 more

Conditions: Intestinal Disease
Interventions: Neostigmine Injectable Solution, Sugammadex injection; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Migraine, Facial Pain or Pressure, Headache
Interventions: Topical solution of 4% lidocaine, Saline 0.9%; Drug
Lead sponsor: Association of Migraine Disorders; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
Interventions: ONCOS-102, Durvalumab, Cyclophosphamide; Biological · Drug
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: San Diego, California • Miami, Florida • Buffalo, New York + 3 more

Conditions: Healthy
Interventions: Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Insulin Resistance
Interventions: Hypertonic Saline (3% NaCl), Isotonic Saline (0.9% NaCl); Other
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: 30 Years to 50 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Drain Output After Breast Reduction Surgery, Breast Reductions
Interventions: IV TXA, Topical TXA, Topical saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19
Interventions: VYD2311-SD, VYD2311-MD, Placebo; Drug
Lead sponsor: Invivyd, Inc.; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 1,770 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 20
States / cities: Long Beach, California • San Diego, California • Orlando, Florida + 17 more

Conditions: Cystic Fibrosis
Interventions: 7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS); Drug
Lead sponsor: CF Therapeutics Development Network Coordinating Center; Network
Eligibility: 4 Months to 59 Months
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 24 more

Conditions: Femoroacetabular Impingement, Chondral Lesions
Interventions: Platelet-rich plasma (PRP), Saline; Biological · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Coronary Artery Disease, Sternal Pain
Interventions: Bupivacaine Group, Placebo; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infections, Urinary Tract
Interventions: GSK2251052, imipenem-cilastatin, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Council Bluffs, Iowa • Topeka, Kansas + 1 more

Conditions: Surgery
Interventions: 0.9% Saline warmed to 37 degrees Celsius, 0.9% Saline warmed to 24 degrees Celsius; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Scar Prevention, Scar Reduction
Interventions: AZX100 Drug Product, Placebo; Drug
Lead sponsor: Capstone Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Pasadena, California • Philadelphia, Pennsylvania • Austin, Texas

Conditions: HIV-1 Infection
Interventions: MVA.tHIVconsv3, MVA.tHIVconsv4, Placebo; Biological · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: Erythromycin, Placebo, Magnetic Resonance Imaging, Barium Sulfate Solution; Drug · Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ischemic Stroke
Interventions: Verapamil and Magnesium Sulfate, Placebo; Drug · Other
Lead sponsor: Justin Fraser; Other
Eligibility: 18 Years to 101 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hip Fractures
Interventions: Tranexamic acid, Normal Saline; Drug
Lead sponsor: Community Memorial Health System; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Ventura, California

Conditions: Intradialytic Hypotension
Interventions: Icatibant, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy Volunteer Subjects
Interventions: Trehalose for IV Infusion, Saline 0.9% IV; Drug
Lead sponsor: Bioblast Pharma Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postoperative Wound Haemorrhage
Interventions: Tranexamic acid, normal saline; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Columbia, Missouri

Search by objective public record fields.

A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Sleep and Healthy Aging Research on Depression for Younger Women

STOP-T1D Low-Dose (ATG)

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

Visual Instillation of Sphenopalatine-block Intervention for ONgoing Migraine

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

The Effect of Vasopressin on Glucose Regulation

Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery

Study of VYD2311 for the Prevention of COVID-19

Infant Study of Inhaled Saline in Cystic Fibrosis

Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip

Pecto-Intercostal Fascial Block for Postoperative Analgesia After Cardiac Surgery

GSK2251052 in Complicated Urinary Tract Infection

Solution Temperature and Fluid Deficit During Hysteroscopy

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults

Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility

Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.

Blood Loss After Early TXA in Hip Fractures.

Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery